Soon after the discovery of radium by Madam Curie, its life saving property was recognized followed by its life threatening property. Since then a large number of radioactive isotopes are used for diagnostic and curative purposes. The focus was shifted from radium to the short-lived reactor produced radionuclides, like 99mTc. Accelerator produced radionuclides like 18F, 67Ga, 201Tl, 211At, completed the reactor-produced radionuclides portfolio from late nineties. Light charged particle (p, d or α) induced reactions are mainly used for production of these clinically important radionuclides while heavy ion assisted reactions are also feasible in some cases. Our group is involved in producing chemical, physical and nuclear data for heavy ion induced production of radioisotopes for last two decades. We studied heavy ion induced reaction mechanisms and excitation functions of a selection of important radionuclides covering the entire nuclide chart. We have also developed radiochemical methods to separate no-carrier-added radionuclides from the target matrix. Astatine and technetium are two elements in the spotlight of nuclear medicine. 211At is used for targeted therapy due to its suitable half-life and high energy a-particles. At radionuclides are mostly produced through the a-induced reactions on Bi target. In recent years, we have studied in details the heavy ion (6,7Li, 9Be) induced production routes of astatine radionuclides on natural Pb and Tl targets and on separation of astatine from the corresponding targets. Similarly, apart from widely used 99mTc, other Tc tracers (93Tc, 94mTc, 94Tc, 95mTc, 95Tc and 96Tc) have got appreciation in serving diverse applications. We made attempts to produce Tc tracers via 7Li and 9Be induced reactions on natural Zr and Y targets and also developed radiochemical separation methodologies for the no-carrier-added Tc radionuclides. However, after the Fukushima incident various social and political constrains are becoming more stringent for setting up new reactor facilities for isotope production. Upcoming large-scale facilities like neutron spallation sources are now in the focus of discussions as alternative sources of clinically important radionuclides. In this spirit CERN has launched the CERN-MEDICIS project as a unique facility for the production of large quantities of radionuclides dedicated to biomedical research based on the spallation of suitable targets by high-energy proton beams. The most striking feature of this program is that the isotope production is relying much more in the physical separation of the radionuclides rather than their chemical separation. For instance 149Tb and 225Ra (as generator of 213Bi) separated beams can be used to produce therapeutic doses for upcoming pre-clinical and clinical trials. I would like to discuss the entire evolution of clinically important radionuclides with special emphasis on our work on heavy ion activation and finally CERN-MEDICIS.